Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc (NQ: XENE )

40.10 +0.60 (+1.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 255,970
Open 39.33
Bid (Size) 40.09 (9)
Ask (Size) 40.16 (4)
Prev. Close 39.50
Today's Range 38.85 - 40.82
52wk Range 27.98 - 50.99
Shares Outstanding 63,562,303
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire

Performance

YTD
-10.71%
-10.71%
1 Month
-6.09%
-6.09%
3 Month
-8.93%
-8.93%
6 Month
+21.70%
+21.70%
1 Year
+0.83%
+0.83%

More News

Read More
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Earnings Scheduled For February 29, 2024
Via Benzinga
Earnings Outlook For Xenon Pharmaceuticals
Via Benzinga
4 Analysts Have This to Say About Xenon Pharmaceuticals
Via Benzinga
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Via InvestorPlace
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Via Benzinga
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Via MarketBeat
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Why Xenon Pharmaceuticals Stock (XENE) Is Seeing Blue Skies Today
Via Benzinga
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Announces Proposed Public Offering
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Xenon Pharma's Depression Candidate Shows Positive Signals Of Efficacy, Despite Primary Endpoint Miss: Analyst
Via Benzinga
Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring
Via Investor's Business Daily
What's Going On With Neurology-Focused Xenon Pharmaceuticals' Stock Today?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.